Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYMR Kymera Therapeutics	$44.10 +3.5%	$44.23	$19.44 ▼ $53.27	$3.15B	2.18	743,805 shs	508,269 shs
LGND Ligand Pharmaceuticals	$159.08 +1.1%	$130.41	$93.58 ▼ $161.93	$3.12B	0.85	148,444 shs	234,074 shs
PHGUF Pharming Group	$1.30 +12.1%	$1.15	$0.75 ▼ $1.30	$872.40M	0.65	8,923 shs	300 shs
SRRK Scholar Rock	$35.49 +2.6%	$35.65	$6.76 ▼ $46.98	$3.41B	0.48	1.27 million shs	2.05 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYMR Kymera Therapeutics	+0.57%	+2.50%	-6.93%	+44.42%	-12.28%
LGND Ligand Pharmaceuticals	+1.33%	+2.29%	+18.76%	+54.83%	+48.29%
PHGUF Pharming Group	0.00%	0.00%	+0.87%	+16.00%	+40.62%
SRRK Scholar Rock	+0.55%	+7.12%	-13.48%	+15.30%	+273.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KYMR Kymera Therapeutics	3.0292 of 5 stars	4.6	1.0	0.0	0.0	2.6	2.5	0.0
LGND Ligand Pharmaceuticals	4.0793 of 5 stars	1.5	3.0	0.0	4.4	4.0	2.5	1.9
PHGUF Pharming Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	4.5341 of 5 stars	4.6	0.0	0.0	4.4	2.8	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KYMR Kymera Therapeutics	3.10	Buy	$59.11	34.04% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$157.00	-1.31% Downside
PHGUF Pharming Group	0.00	N/A	N/A	N/A
SRRK Scholar Rock	3.20	Buy	$45.75	28.91% Upside

Current Analyst Ratings Breakdown

Latest PHGUF, KYMR, SRRK, and LGND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	SRRK Scholar Rock	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$50.00
8/8/2025	LGND Ligand Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$155.00 ➝ $185.00
8/7/2025	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $45.00
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/30/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$145.00 ➝ $162.00
7/30/2025	SRRK Scholar Rock	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Strong-Buy	$53.00
7/17/2025	SRRK Scholar Rock	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00
6/27/2025	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$56.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KYMR Kymera Therapeutics	$47.07M	66.99	N/A	N/A	$13.59 per share	3.25
LGND Ligand Pharmaceuticals	$167.13M	18.66	$1.65 per share	96.62	$42.28 per share	3.76
PHGUF Pharming Group	$297.20M	2.94	$0.01 per share	154.36	$0.33 per share	3.94
SRRK Scholar Rock	$33.19M	102.79	N/A	N/A	$2.43 per share	14.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KYMR Kymera Therapeutics	-$223.86M	-$3.47	N/A	N/A	N/A	-616.03%	-31.60%	-27.12%	10/30/2025 (Estimated)
LGND Ligand Pharmaceuticals	-$4.03M	-$4.00	N/A	42.88	N/A	-40.44%	-9.21%	-8.09%	11/6/2025 (Estimated)
PHGUF Pharming Group	-$11.84M	N/A	0.00	∞	N/A	-2.19%	-3.38%	-1.82%	11/6/2025 (Estimated)
SRRK Scholar Rock	-$246.29M	-$2.91	N/A	N/A	N/A	N/A	-127.11%	-90.09%	N/A

Latest PHGUF, KYMR, SRRK, and LGND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.83	-$0.95	-$0.12	-$0.95	$17.37 million	$11.48 million
8/7/2025	Q2 2025	LGND Ligand Pharmaceuticals	$1.54	$1.60	+$0.06	$0.24	$43.87 million	$47.63 million
8/6/2025	Q2 2025	SRRK Scholar Rock	-$0.66	-$0.98	-$0.32	-$0.98	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHGUF Pharming Group	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KYMR Kymera Therapeutics	N/A	8.32	8.32
LGND Ligand Pharmaceuticals	N/A	5.45	5.21
PHGUF Pharming Group	0.51	2.76	2.00
SRRK Scholar Rock	0.21	6.33	6.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KYMR Kymera Therapeutics	N/A
LGND Ligand Pharmaceuticals	91.28%
PHGUF Pharming Group	N/A
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
KYMR Kymera Therapeutics	16.01%
LGND Ligand Pharmaceuticals	7.00%
PHGUF Pharming Group	N/A
SRRK Scholar Rock	13.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KYMR Kymera Therapeutics	170	71.50 million	60.05 million	Optionable
LGND Ligand Pharmaceuticals	80	19.60 million	18.23 million	Optionable
PHGUF Pharming Group	382	671.07 million	N/A	Not Optionable
SRRK Scholar Rock	140	96.13 million	83.34 million	Optionable

PHGUF, KYMR, SRRK, and LGND Headlines

Recent News About These Companies

Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD

August 21 at 12:52 PM | insidermonkey.com

Scholar Rock assumed with a Buy at Jefferies

August 21 at 9:02 AM | msn.com

A Closer Look at Scholar Rock (SRRK) Valuation Following Landmark Phase 3 Data and FDA Priority Review

August 21 at 9:02 AM | finance.yahoo.com

Lord Abbett & CO. LLC Boosts Holdings in Scholar Rock Holding Corporation (NASDAQ:SRRK)

August 17, 2025 | marketbeat.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 15, 2025 | businesswire.com

Scholar Rock publishes SAPPHIRE trial data in The Lancet

August 15, 2025 | msn.com

Scholar Rock Holding: Upcoming Milestone Approaches

August 13, 2025 | seekingalpha.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Shares Sold by Informed Momentum Co LLC

August 13, 2025 | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives $45.14 Average PT from Brokerages

August 13, 2025 | americanbankingnews.com

Scholar Rock’s Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss

August 12, 2025 | msn.com

Cantor Fitzgerald Lowers Earnings Estimates for Scholar Rock

August 12, 2025 | americanbankingnews.com

Wedbush Issues Negative Forecast for Scholar Rock Earnings

August 12, 2025 | americanbankingnews.com

Analysts Offer Predictions for Scholar Rock FY2025 Earnings

August 11, 2025 | marketbeat.com

Wedbush Brokers Lower Earnings Estimates for Scholar Rock

August 11, 2025 | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Rating of "Buy" from Analysts

August 11, 2025 | marketbeat.com

XTX Topco Ltd Takes Position in Scholar Rock Holding Corporation (NASDAQ:SRRK)

August 10, 2025 | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Q2 2025 Earnings Call Transcript

August 9, 2025 | msn.com

Scholar Rock (NASDAQ:SRRK) Stock Price Down 10.2% Following Weak Earnings

August 8, 2025 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Price Target Lowered to $45.00 at BMO Capital Markets

August 8, 2025 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Shares Gap Down After Earnings Miss

August 7, 2025 | marketbeat.com

Scholar Rock outlines Q3 2025 U.S. apitegromab launch plans amid regulatory progress and global expansion focus

August 7, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHGUF, KYMR, SRRK, and LGND Company Descriptions

Kymera Therapeutics NASDAQ:KYMR

$44.10 +1.51 (+3.55%)

Closing price 04:00 PM Eastern

Extended Trading

$44.14 +0.05 (+0.10%)

As of 05:03 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Ligand Pharmaceuticals NASDAQ:LGND

$159.08 +1.77 (+1.13%)

Closing price 04:00 PM Eastern

Extended Trading

$159.07 -0.01 (-0.01%)

As of 04:35 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Pharming Group OTCMKTS:PHGUF

$1.30 +0.14 (+12.07%)

As of 10:21 AM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Scholar Rock NASDAQ:SRRK

$35.49 +0.90 (+2.60%)

Closing price 04:00 PM Eastern

Extended Trading

$35.70 +0.20 (+0.58%)

As of 06:56 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time